TheEdgeResearch
Home / Stocks / ABVC

ABVC BioPharma, Inc. (ABVC)

NASDAQ Healthcare Biotechnology
$0.87 ▼ -1.56%
Market Cap
$23.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.50
52-Wk Range
0.7069-2.87
CEO
Uttam Yashwant Patil
Country
US
Currency
USD

ABVC BioPharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fremont, CA, US. The stock last traded at $0.87, down 1.56% on the session, giving a market capitalisation of $23.4M. On trailing twelve-month figures it carries a trailing P/E of -4.30, a net margin of 591.8%. Its beta of 0.50 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.30
Price / Sales
-29.36
Price / Book
1.77
EV / EBITDA
-3.67
Gross margin
100.0%
Operating margin
827.6%
Net margin
591.8%
Return on equity
—
Debt / equity
0.19
Current ratio
0.20
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
18
IPO date
2004-11-10
Headquarters
Fremont, CA, US
About ABVC BioPharma, Inc.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Comparable companies

ABVC BioPharma, Inc. is most often compared with the following Healthcare names:

ATNMFGENGRCEJUNSLTRNLVTXPDSBRVPHTVRDXLO
More research on ABVC
ABVC technical analysis ABVC TheEdge Score Compare against peers
Open full interactive analysis & DCF →